Sugi Predict

Sugi Predict / Compounds / SCHEMBL6489450

SCHEMBL6489450

SCHEMBL6489450

Fc1cc(F)cc(CCI)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ CASP1 P29466 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ IDO1 P14902 2/20 0.42
▸ DAO P14920 2/20 0.39
▸ CYP17A1 P05093 1/20 0.39
▸ CYP21A2 P08686 1/20 0.39
▸ CYP11B1 P15538 1/20 0.39
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ PTGS1 P23219 1/20 0.34
▸ PTGS2 P35354 1/20 0.34
▸ TAAR1 Q96RJ0 2/20 0.33
▸ DBH P09172 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16105495 0.82 IDO1 (0.50) IDO1DAOCYP17A1CYP21A2CYP11B1
SCHEMBL18475171 0.77 IDO1 (0.46) IDO1DAOCA12CA1CA9
SCHEMBL6487330 0.75 TAAR1 (0.63) ALDH1A1HPGDALOX15ALOX12CASP1
SCHEMBL31650900 0.74 IDO1 (0.44) IDO1DAOCYP17A1CYP21A2CYP11B1
SCHEMBL755085 0.74 TAAR1 (0.59) ALDH1A1HPGDALOX15ALOX12CASP1
SCHEMBL28041238 0.74 MAOA (0.46) ALDH1A1HPGDALOX15ALOX12CASP1
SCHEMBL16630368 0.74 CYP11B1 (0.39) ALDH1A1HPGDALOX15ALOX12CASP1
SCHEMBL294824 0.72 IDO1 (0.42) IDO1DAOCYP17A1CYP21A2CYP11B1
SCHEMBL3127720 0.72 IDO1 (0.42) IDO1DAOCYP17A1CYP21A2CYP11B1
SCHEMBL1154666 0.72 IDO1 (0.42) ALDH1A1IDO1DAOCYP17A1CYP21A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF SCHRÖDINGER, INC. 2020-04-02 — — US disclosed
US-10472374-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2019-11-12 — — US disclosed
EP-3329919-B1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO LLC (US) 2019-11-06 — — EP disclosed
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. 2019-01-17 — — US disclosed
EP-3329919-A1 ACC INHIBITORS AND USES THEREOF Gilead Apollo, LLC (US) 2018-06-06 — — EP disclosed
US-9944655-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-04-17 — — US disclosed
US-9944655-B2 ACC inhibitors and uses thereof GILEAD APOLLO, LLC (US) 2018-04-17 — — US disclosed
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-10-13 — — US disclosed
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2016-10-13 — — US disclosed
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2015-07-23 — — US disclosed
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF GILEAD APOLLO, LLC 2015-07-23 — — US disclosed
US-8969557-B2 ACC inhibitors and uses thereof Nimbus Apollo, Inc. (US) 2015-03-03 — — US disclosed
US-8969557-B2 ACC inhibitors and uses thereof Nimbus Apollo, Inc. (US) 2015-03-03 — — US disclosed
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — US disclosed
WO-2013071169-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — WO disclosed
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF Nimbus Apollo, Inc. (US) 2013-05-16 — — US disclosed
US-20050240034-A1 Artemisinin-based peroxide compounds as broad spectrum anti-infective agents MISSISSIPPI, THE UNIVERSITY OF 2005-10-27 — — US disclosed
WO-2003095444-A1 ARTEMISININ-BASED PEROXIDE COMPOUNDS AS BROAD SPECTRUM ANTI-INFECTIVE AGENTS UNIVERSITY OF MISSISSIPI (US) 2003-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200102323-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ALDH1A1 104/4885HPGD 872/4885ALOX15 685/4885
US-20150203510-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ALDH1A1 104/4885HPGD 872/4885ALOX15 685/4885
US-10472374-B2 ACC inhibitors and uses thereof ACACA, ACACB, ACAT2 ALDH1A1 104/4885HPGD 872/4885ALOX15 685/4885
US-20190016732-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ALDH1A1 104/4885HPGD 872/4885ALOX15 685/4885
US-20050240034-A1 Artemisinin-based peroxide compounds as broad spectrum anti-infective agents CASP10, HCCS, CASP9 ALDH1A1 192/4885HPGD 449/4885ALOX15 181/4885
US-20130123231-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ALDH1A1 104/4885HPGD 872/4885ALOX15 685/4885
US-20160297834-A1 ACC INHIBITORS AND USES THEREOF ACACA, ACACB, ACAT2 ALDH1A1 104/4885HPGD 872/4885ALOX15 685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.